AYTU BIOPHARMA, INC
Moat Score — Aytu BioPharma, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Aytu holds formulation patents around its orally disintegrating tablet ADHD products, providing some protection, though the underlying active pharmaceutical ingredients are widely available as generics, limiting the depth of this intellectual property moat. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small specialty pharma, Aytu has no meaningful manufacturing or scale cost advantage and instead relies on differentiated formulation value rather than cost leadership to compete. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Aytu's branded products compete against a dominant base of low-cost generic ADHD medications, meaning pricing power is limited to the narrower patient population that specifically needs its differentiated formulation. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in Aytu's specialty pharmaceutical business; revenue is driven by individual prescriber relationships and product differentiation rather than any participant network. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Pediatric patients and families who have established a routine with a specific orally disintegrating tablet formulation, and prescribers comfortable with a given product's dosing, show some inertia against switching, but generic alternatives remain an easy substitute for most patients. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | Aytu operates at a small scale relative to large pharmaceutical and generic manufacturers, and its niche categories do not require or confer an efficient-scale barrier to entry against well-capitalized competitors. |